Cancer Risks

Second Cancer Risks

Management From Family History Not Enough

Associated Syndrome

Associated Syndrome

BRCA1 Cancer Risk Table

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION *
Female Breast To age 50 28%-51% 1.9%
  To age 70 46%-87% 7.1%
  Second primary within 5 years of first breast cancer diagnosis 13%-20% 2%
Ovarian To age 50 8%-23% 0.2%
  To age 70 39%-63% 0.7%
  Ovarian cancer within 10 years of a breast cancer diagnosis 12.7% <1.0%
Prostate To age 70 Up to 16% 6.6%
Male Breast To age 70 1.2% <0.1%
Pancreatic To age 80 Elevated risk 1%

BRCA1 Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Female Breast Breast awareness – Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. 18 years NA
  Clinical breast examination 25 years Every 6 to 12 months
  Breast MRI with contrast and/or Mammography with consideration of tomosynthesis Age 25 for MRI, or if MRI is unavailable, mammography with consideration of tomosynthesis. Age 30 for both MRI and mammography. Individualize to a younger age if a relative has been diagnosed younger than age 30. Annually
  Consider investigational screening studies within clinical trials. Individualized NA
  Consider risk-reducing mastectomy. Individualized NA
  Consider options for breast cancer risk reduction agents (i.e. tamoxifen). Individualized NA
Ovarian Bilateral salpingo-oophorectomy, , including discussion of hysterectomy considering the possible increased risk for serous uterine cancer 35 to 40 years, upon completion of childbearing NA
  Consider transvaginal ultrasound and CA-125 measurement. Consider investigational screening studies within clinical trials. 30 to 35 years Individualized
  Consider options for ovarian cancer risk reducing agents (i.e. oral contraceptives). Individualized NA
Prostate Consider prostate cancer screening. 45 years Individualized
  Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be included as part of the risk and benefit discussion about prostate cancer screening. NA NA
  Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be considered when choosing management options for men with a diagnosis of prostate cancer. NA NA
Male Breast Breast self-examination 35 years Monthly
  Clinical breast examination 35 years Annually
Pancreatic For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols. Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family Annually
  Provide education about smoking cessation to reduce pancreatic cancer risk. Individualized Individualized
For Patients With A Cancer Diagnosis For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors) NA NA

 

BRCA2 Cancer Risk Table

CANCER TYPE AGE RANGE CANCER RISK RISK FOR GENERAL POPULATION *
Female Breast To age 50 23%-35% 1.9%
  To age 70 43%-84% 7.1%
  Second primary within 5 years of first breast cancer diagnosis 8%-12% 2%
Ovarian To age 50 0.4%-4% 0.2%
  To age 70 15%-27% 0.7%
  Ovarian cancer within 10 years of a breast cancer diagnosis 6.8% <1.0%
Pancreatic To age 80 7%, or higher if there is a family history of pancreatic cancer. 1%
Male Breast To age 70 6.8% <0.1%
Prostate To age 70 20% 6.6%
Melanoma To age 80 Elevated risk for melanomas of both the skin and eye 1.6%

BRCA2 Cancer Risk Management Table

CANCER TYPE PROCEDURE AGE TO BEGIN FREQUENCY
Female Breast Breast awareness – Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness. 18 years NA
  Clinical breast examination 25 years Every 6 to 12 months
  Breast MRI with contrast and/or Mammography with consideration of tomosynthesis Age 25 for MRI or if MRI is unavailable, mammography with consideration of tomosynthesis. Age 30 for both MRI and mammography. Individualize to a younger age if a relative has been diagnosed younger than age 30. Annually
  Consider investigational screening studies within clinical trials. Individualized NA
  Consider risk-reducing mastectomy. Individualized NA
  Consider options for breast cancer risk reduction agents (i.e. tamoxifen). Individualized NA
Ovarian Bilateral salpingo-oophorectomy 35 to 45 years, upon completion of childbearing NA
  Consider transvaginal ultrasound and CA-125 measurement. Consider investigational screening studies within clinical trials. 30 to 35 years Individualized
  Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives). Individualized NA
Pancreatic For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols. Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family Annually
  Provide education about smoking cessation to reduce pancreatic cancer risk Individualized Individualized
Male Breast Breast self-examination 35 years Monthly
  Clinical breast examination 35 years Annually
Prostate  Recommend prostate cancer screening. 40 to 45 years, or 10 years younger than the earliest prostate cancer diagnosis in the family Annually, or adjusted based on results from first PSA screen
  Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be included as part of the risk and benefit discussion about prostate cancer screening. NA NA
  Since mutation carriers are at an increased risk for more aggressive prostate cancer this information may be considered when choosing management options for men with a diagnosis of prostate cancer. NA NA
Melanoma Consider whole-body skin and eye examinations. Individualized N/A
For Patients With A Cancer Diagnosis For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors) NA NA

Medical Management

Medical Management

Medical Management

Medical Management

Unique Challenges

Unique Challenges

Unique Challenges